Company: SUNE
Filing Date: 2025-04-22
Form Type: S-3
Source: 0001213900-25-033892
Chunk: 11

Company: SUNation Energy, Inc.
Filing Date: 2025-04-22
Form: S-3
Chunk 11
---
, we had 652,174 shares of the common stock that may be issued upon the exercise of outstanding warrants,
all of which are fully exercisable.

‎

Resales of our common stock in the public market during an offering by our stockholders may cause the market price of our common stock to fall.

We may issue common or preferred stock from time
to time in connection with an offering. The issuance from time to time of these new shares, or our ability to issue these shares, could
result in resales of our by our current stockholders concerned about the potential dilution of their holdings. In turn, these resales
could have the effect of depressing the market price for our common stock.

<div align='center'>5</div>

Our shares will be subject to potential delisting if we do not maintain the listing requirements of the Nasdaq Capital Market.

The shares of our common stock are listed on the
Nasdaq Capital Market, or Nasdaq. Nasdaq has rules for continued listing, including, without limitation, minimum market capitalization
and other requirements. Failure to maintain our listing, or de-listing from Nasdaq, would make it more difficult for shareholders to dispose
of our common stock and more difficult to obtain accurate price quotations on our common stock. This could have an adverse effect on the
price of our common stock. Our ability to issue additional securities for financing or other purposes, or otherwise to arrange for any
financing we may need in the future, may also be materially and adversely affected if our common stock is not traded on a national securities
exchange. On April 11, 2025, we received a new non-compliance notice notifying the Company that, for the 30 consecutive business day period
immediately preceding deficiency letter, the Company’s common stock had not maintained a minimum closing bid price of $1.00 per
share (the “Minimum Bid Price Requirement”) and, as a result, does not comply with Listing Rule 5550(a)(2) (the “Rule”).
Normally, a company would be afforded a 180-calendar day period (“Cure Period”) to demonstrate compliance with such deficiency;
however, pursuant to Listing Rule 5810(c)(3)(A)(iv), the Company is not eligible for a customary Cure Period specified in Rule 5810(c)(3)(A)
due to the fact that the Company has effected a reverse stock split over the prior one-year period or has effected one or more reverse
stock splits over the prior two